2 July 2024 - Australians with early breast cancer, leukaemia, and types of lupus, and insomnia, will now have access to new and expanded treatment options under the PBS.

Olaparib (Lynparza) has been expanded for use for patients with human epidermal growth factor receptor 2 negative (HER2-negative) high-risk early breast cancer with specific gene mutations.

Read Assistant Minister for Health and Aged Care press release